The present invention relates generally to collecting and evaluating information related to sleep quality.
Sleep is generally beneficial and restorative to a patient, exerting great influence on the quality of life. The human sleep/wake cycle generally conforms to a circadian rhythm that is regulated by a biological clock. Regular periods of sleep enable the body and mind to rejuvenate and rebuild. The body may perform various tasks during sleep, such as organizing long term memory, integrating new information, and renewing tissue and other body structures.
Normal sleep is characterized by a general decrease in metabolic rate, body temperature, blood pressure, breathing rate, heart rate, cardiac output, sympathetic nervous activity, and other physiological functions. However, studies have shown that the brain's activity does not decrease significantly during sleep. Normally a patient alternates between rapid eye movement (REM) and non-REM (NREM) sleep in approximately 90 minute cycles throughout a sleep period. A typical eight hour sleep period may be characterized in terms of a five-step sleep cycle identifiable through EEG brain wave activity.
Non-REM sleep includes four sleep states or stages that range from light dozing to deep sleep. Throughout NREM sleep, muscle activity is still functional, breathing is low, and brain activity is minimal. Approximately 85% of the sleep cycle is spent in NREM sleep. Stage 1 NREM sleep may be considered a transition stage between wakefulness and sleep. As sleep progresses to stage 2 NREM sleep, eye movements become less frequent and brain waves increase in amplitude and decrease in frequency. As sleep becomes progressively deeper, the patient becomes more difficult to arouse. Stage 3 sleep is characterized by 20 to 40% slow brain wave (delta) sleep as detected by an electroencephalogram (EEG). Sleep stages 3 and 4 are considered to be the most restful sleep stages.
REM sleep is associated with more prevalent dreaming, rapid eye movements, muscle paralysis, and irregular breathing, body temperature, heart rate and blood pressure. Brain wave activity during REM sleep is similar to brain wave activity during a state of wakefulness. There are typically 4-6 REM periods per night, with increasing duration and intensity toward morning. While dreams can occur during either REM or NREM sleep, the nature of the dreams varies depending on the type of sleep. REM sleep dreams tend to be more vivid and emotionally intense than NREM sleep dreams. Furthermore, autonomic nervous system activity is dramatically altered when REM sleep is initiated.
Lack of sleep and/or decreased sleep quality may be have a number of causal factors including, e.g., nerve or muscle disorders, respiratory disturbances, and emotional conditions, such as depression and anxiety. Chronic, long-term sleep-related disorders e.g., chronic insomnia, sleep-disordered breathing, and sleep movement disorders, including restless leg syndrome (RLS), periodic limb movement disorder (PLMD) and bruxism, may significantly affect a patient's sleep quality and quality of life.
Movement disorders such as restless leg syndrome (RLS), and a related condition, denoted periodic limb movement disorder (PLMD), are emerging as one of the more common sleep disorders, especially among older patients. Restless leg syndrome is a disorder causing unpleasant crawling, prickling, or tingling sensations in the legs and feet and an urge to move them for relief. RLS leads to constant leg movement during the day and insomnia or fragmented sleep at night. Severe RLS is most common in elderly people, although symptoms may develop at any age. In some cases, it may be linked to other conditions such as anemia, pregnancy, or diabetes.
Many RLS patients also have periodic limb movement disorder (PLMD), a disorder that causes repetitive jerking movements of the limbs, especially the legs. These movements occur approximately every 20 to 40 seconds and cause repeated arousals and severely fragmented sleep.
A significant percentage of patients between 30 and 60 years experience some symptoms of disordered breathing, primarily during periods of sleep. Sleep disordered breathing is associated with excessive daytime sleepiness, systemic hypertension, increased risk of stroke, angina and myocardial infarction. Disturbed respiration can be particularly serious for patients concurrently suffering from cardiovascular deficiencies. Disordered breathing is particularly prevalent among congestive heart failure patients, and may contribute to the progression of heart failure.
Sleep apnea is a fairly common breathing disorder characterized by periods of interrupted breathing experienced during sleep. Sleep apnea is typically classified based on its etiology. One type of sleep apnea, denoted obstructive sleep apnea, occurs when the patient's airway is obstructed by the collapse of soft tissue in the rear of the throat. Central sleep apnea is caused by a derangement of the central nervous system control of respiration. The patient ceases to breathe when control signals from the brain to the respiratory muscles are absent or interrupted. Mixed apnea is a combination of the central and obstructive apnea types. Regardless of the type of apnea, people experiencing an apnea event stop breathing for a period of time. The cessation of breathing may occur repeatedly during sleep, sometimes hundreds of times a night and occasionally for a minute or longer.
In addition to apnea, other types of disordered respiration have been identified, including, for example, hypopnea (shallow breathing), dyspnea (labored breathing), hyperpnea (deep breathing), and tachypnea (rapid breathing).
Combinations of the disordered respiratory events described above have also been observed. For example, Cheyne-Stokes respiration (CSR) is associated with rhythmic increases and decreases in tidal volume caused by alternating periods of hyperpnea followed by apnea and/or hypopnea. The breathing interruptions of CSR may be associated with central apnea, or may be obstructive in nature. CSR is frequently observed in patients with congestive heart failure (CHF) and is associated with an increased risk of accelerated CHF progression.
An adequate duration and quality of sleep is required to maintain physiological homeostasis. Untreated, sleep disturbances may have a number of adverse health and quality of life consequences ranging from high blood pressure and other cardiovascular disorders to cognitive impairment, headaches, degradation of social and work-related activities, and increased risk of automobile and other accidents.
Various modifications and additions can be made to the preferred embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof.
Various embodiments of present invention involve methods and systems for collecting sleep quality data and evaluating the sleep quality of a patient.
An embodiment of the invention involves a method for collecting sleep quality data. The method includes detecting physiological and non-physiological conditions associated with the sleep quality of a patient and collecting sleep quality data based on the detected conditions. Collecting the sleep quality data is performed at least in part implantably.
Another embodiment of the invention involves a method for evaluating sleep quality. In accordance with this method, one or more metrics associated with sleep are determined. One or more metrics associated with events that disrupt sleep are determined. A composite sleep quality metric is determined using the one or more metrics associated with sleep and the one or more metrics associated with events that disrupt sleep.
In yet another embodiment of the invention, a method for evaluating sleep quality includes detecting physiological and non-physiological conditions associated with the sleep quality of a patient and collecting sleep quality data based on the detected conditions. The sleep quality of the patient is evaluated using the collected data. At least one of collecting the sleep quality data and evaluating the sleep quality of the patient is performed at least in part implantably.
Another embodiment of the invention involves a method for evaluating sleep quality. One or more conditions associated with sleep quality of a patient are detected during a period of wakefulness. Sleep quality data is collected based on the detected conditions. The patient's sleep quality is evaluated using the collected sleep quality data. At least one of collecting the data and evaluating the sleep quality is performed at least in part implantably.
A further embodiment of the invention involves a medical device including a detector system configured to detect physiological and non-physiological conditions associated with sleep quality and a data collection system for collecting sleep quality data based on the detected conditions. The data collection system includes an implantable component.
Yet another embodiment of the invention relates to a medical device configured to evaluate sleep quality. The medical device includes a detector system configured to detect physiological and non-physiological conditions associated with the sleep quality of a patient. A sleep quality processor, coupled to the detection system, is configured to determine metrics based on the detected conditions. The metrics include one or more metrics associated with sleep, one or more metrics associated with events that disrupt sleep, and at least one composite sleep quality metric based on the one or more metrics associated with sleep and the one or more metrics associated with events that disrupt sleep.
In another embodiment of the invention, a medical device for assessing sleep quality includes a detector unit configured to detect physiological and non-physiological conditions associated with sleep quality and a sleep quality data collection unit configured to collect sleep quality data based on the detected conditions. A data analysis unit coupled to the data collection unit evaluates sleep quality based on the collected sleep quality data. At least one of the data collection unit and the data analysis unit includes an implantable component.
A further embodiment of the invention involves a system for collecting sleep quality data. The system includes means for detecting physiological and non-physiological conditions associated with sleep quality and means for collecting sleep quality data based on the detected conditions. The means for collecting the sleep quality data includes an implantable component.
In yet another embodiment of the invention, a system for assessing sleep quality includes means for determining one or more metrics associated with sleep and means for determining one or more metrics associated with events that disrupt sleep. The system further includes means for determining a composite sleep quality metric as a function of the metrics associated with sleep and the metrics associated with events that disrupt sleep.
Another embodiment of the invention involves a system for evaluating sleep quality. The system includes means for detecting physiological and non-physiological conditions associated with sleep quality and means for collecting sleep quality data based on the detected conditions. The system includes means for evaluating the sleep quality of the patient based on the collected sleep quality data. At least one of the means for collecting the sleep quality data and the means for evaluating the sleep quality comprise an implantable component.
A further embodiment involves a system for evaluating the sleep quality of a patient. The system includes means for detecting one or more patient conditions associated with sleep quality during a period of wakefulness and means for collecting sleep quality data based on the detected conditions. The system further includes means for evaluating the sleep quality of the patient using the collected sleep quality data. At least one of the means for collecting the sleep quality data and means for evaluating the sleep quality include an implantable component.
The above summary of the present invention is not intended to describe each embodiment or every implementation of the present invention. Advantages and attainments, together with a more complete understanding of the invention, will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail below. It is to be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
In the following description of the illustrated embodiments, references are made to the accompanying drawings which form a part hereof, and in which are shown, by way of illustration, various embodiments by which the invention may be practiced. It is to be understood that other embodiments may be utilized. Structural and functional changes may be made without departing from the scope of the present invention.
Sleep quality assessments depend upon acquiring sleep-related data, including the patient's typical sleep patterns and the physiological, environmental, contextual, emotional, and other conditions affecting the patient during sleep. Diagnosis of sleep disorders and assessment of sleep quality often involves the use of a polysomnographic sleep study at a dedicated sleep facility. However, such studies are costly, inconvenient to the patient, and may not accurately represent the patient's typical sleep behavior. In a polysomnographic sleep study, the patient is instrumented for data acquisition and observed by trained personnel. Sleep assessment in a laboratory setting presents a number of obstacles in acquiring an accurate picture of a patient's typical sleep patterns. For example, spending a night in a sleep laboratory typically causes a patient to experience a condition known as “first night syndrome,” involving disrupted sleep during the first few nights in an unfamiliar location. In addition, sleeping while instrumented and observed may not result in a realistic perspective of the patient's normal sleep patterns.
Further, polysomnographic sleep studies provide an incomplete data set for the analysis of some sleep disorders, including, for example, sleep disordered breathing. A number of physiological conditions associated with sleep disordered breathing are detectable during periods of wakefulness, e.g., decreased heart rate variability, elevated sympathetic nerve activity, norepinephrine concentration, and increased blood pressure variability. Collection of data during periods of sleep and/or during periods of wakefulness may provide a more complete picture of the patient's sleep quality.
Various aspects of sleep quality, including number and severity of arousals, sleep disordered breathing episodes, nocturnal limb movements, and cardiac, respiratory, muscle, and nervous system functioning may provide important information for diagnosis and/or therapy delivery. An initial step to sleep quality evaluation is an accurate and reliable method for discriminating between periods of sleep and periods of wakefulness. Further, acquiring data regarding the patient's sleep states or stages, including sleep onset, termination, REM, and NREM sleep states may be used in connection sleep quality assessment. For example, the most restful sleep occurs during stages 3 and 4 NREM sleep. One indicator of sleep quality is the percentage of time a patient spends in these sleep stages. Knowledge of the patient's sleep patterns may be used to diagnose sleep disorders and/or adjust patient therapy, including, e.g., cardiac or respiratory therapy. Trending disordered breathing episodes, arousal episodes, and other sleep quality aspects may be helpful in determining and maintaining appropriate therapies for patients suffering from disorders ranging from snoring to chronic heart failure.
The present invention involves methods and systems for acquiring sleep quality data using one or more implantable components. As illustrated in
A representative set of the conditions associated with sleep quality is listed in Table 1. Patient conditions used to evaluate sleep quality may include, for example, both physiological and non-physiological (i.e., contextual) conditions. Physiological conditions associated with sleep quality may be further organized, for example, into conditions of the cardiovascular, respiratory, muscle, and nervous systems, and conditions relating to the patient's blood chemistry.
Contextual conditions may be further subdivided into environmental conditions, body-related conditions and historical/background conditions. Environmental conditions may be broadly defined to include the environmental surroundings affecting the patient, such as ambient light, temperature, humidity, air pollution, noise, and barometric pressure. Body-related conditions may include, for example, patient location, posture, and altitude. Contextual conditions relevant to sleep quality may also include historical or background conditions. For example, a patient's medical/psychological history, gender, age, weight, body mass index, neck size, drug use, and emotional state may be detected and used in connection with sleep quality evaluation and sleep disorder diagnosis. Methods and systems for detecting contextual conditions are described in commonly owned U.S. Pat. No. 7,400,928, which is incorporated herein by reference.
Each of the conditions listed in Table 1 may serve a variety of purposes in evaluating sleep quality. For example, a subset of the conditions may be used to detect whether the patient is asleep and to track the various stages of sleep and arousal incidents. Another subset of the conditions may be used to detect disordered breathing episodes. Yet another subset may be used to detect abnormal limb movements. In one implementation, some or all of the listed conditions may be collected over a relatively long period of time and used to analyze long term sleep quality trends. Trending may be used in connection with an overall assessment of sleep quality and diagnosis and treatment of sleep-disordered breathing, movement disorders, and/or other sleep disorders.
In one implementation, sleep quality analysis may be used within the structure of an advanced patient management system. In this implementation, an advanced patient management system having sleep quality analysis capability allows a physician to remotely and automatically monitor cardiac and respiratory functions, as well as other patient conditions, including information related to sleep quality. In one example, an implantable cardiac rhythm management system, such as a cardiac monitor, pacemaker, defibrillator, or resynchronization device, may be equipped with various telecommunications and information technologies to enable real-time data collection, diagnosis, and treatment of the patient. Systems and methods involving advanced patient management techniques are described in U.S. Pat. Nos. 6,336,903, 6,312,378, 6,270,457, and 6,398,728 which are incorporated herein by reference in their respective entireties.
Table 2 provides examples of how some physiological and non-physiological conditions may be used in connection with sleep quality assessment.
The sleep quality data system 200 may use patient-internal sensors 210 implanted within the body of the patient to detect physiological conditions relevant to sleep quality. The conditions detected using patient-internal sensors 210 may include, for example, heart rate, respiratory pattern, and patient activity.
The system 200 may also use patient-external sensors 220 to detect physiological or non-physiological patient conditions. In one example configuration, whether the patient is snoring may be useful in evaluating sleep quality. Snoring data may be detected using an external microphone and transferred to the sleep quality data collection unit 250. In another configuration, ambient temperature and humidity may be factors related to the patient's sleep quality. The ambient temperature and humidity of the patient's room may be sensed using sensors located near patient. Signals from the temperature and humidity sensors may be transmitted to the data collection unit 250. Limb and/or jaw movements may be sensed using patient-external accelerometers and/or other sensors placed in appropriate locations on or near the patient and transmitted to the data collection unit 250.
Information relevant to sleep quality may also be reported 240 by the patient. According to embodiments of the invention, the patient's self-described conditions, including medication use, tobacco use, perceptions of sleep quality, and/or psychological or emotional state, for example, may be relevant to sleep quality assessment. The patient may enter information about these conditions through an appropriate interface device, such as a medical device programmer, coupled to the sleep quality data collection unit 250.
Some information related to sleep quality may be accessible through information systems 230, including network-based systems. For example, information about the patient's present cardiac, respiratory, or other therapy may be downloaded from an external device via a wireless or wired network. In another example, information about conditions affecting the patient, such as local air quality data, may be accessed through an internet-connected website.
The patient-internal sensors 210, patient-external sensors 220, patient-reported input devices 240, and information systems 230, may be coupled to the data collection unit 250 in a variety of ways. In one example, one or more of the sensors 210, 220, patient-reported input devices 240, and information systems 230 have wireless communication capabilities, such as a wireless Bluetooth communications link, or other proprietary communications protocol. In this implementation, the devices having wireless communication capabilities may remotely transmit signals to the data collection unit 250. In this application, the data collection unit 250 may be configured as an implantable or patient-external device. In other implementations, one or more of the patient-internal sensors 210, patient-external sensors 220, patient-reported input devices 240, and information systems 230 may be coupled to the data collection unit 250 through leads or other wired connections.
The implantable or patient-external data collection unit 250 includes detection circuitry 260 for processing signals from the sensors 210, 220, patient-reported input devices 240, and information systems 230. The detection circuitry 260 may include, for example, amplifiers, filters, A/D converters, signal processors and/or sensor driver circuitry configured to provide sensor signals used in the evaluation of sleep quality. The data collection unit 250 may further include wireless communication circuitry 270 for receiving and transmitting signals to wirelessly connected components.
In one embodiment, the sleep quality data system 200 collects data from the sensors 210, 220, input devices 240, and information systems 230, and stores the collected data in memory 280 prior to further processing or transmission. In another embodiment, the sleep quality data system 200 may transmit the collected data to a separate device (not shown) for storage, analysis, or display.
In a further embodiment, the sleep quality data system 200 may evaluate or further process the collected sleep quality data. For this purpose, the sleep quality data system 200 may optionally include a sleep quality analysis unit 290. In one configuration, the data collection unit 250 and the sleep quality analysis unit 290 are arranged in separate devices. In such a configuration, the data collection unit 250 transfers the collected sleep quality data to the sleep quality analysis unit 290 through a wireless or wired connection. In another configuration, the sleep quality analysis unit 290 and the data collection unit 250 are arranged within the same device which may be a patient-external device or a fully or partially implantable device.
The sleep quality analysis unit 290 may include one or more subsystems useful in sleep quality assessment. The subsystems may include, for example a sleep detector 292 used to detect sleep onset, sleep offset, and arousal, for example. The sleep detector may also detect sleep stages, including the various stages of NREM and REM sleep. The sleep quality analysis unit 290 may include circuitry to detect various sleep-related disorders. For example, the sleep quality analysis unit 290 may include circuitry 294 for detecting disordered breathing and circuitry 295 for detecting abnormal nocturnal movements. Further, the sleep quality analysis unit 290 may include a processor for evaluating sleep quality 296, for example, by calculating one or more metrics quantifying the patient's sleep quality.
The cardiac therapy module 320 analyzes the cardiac signals to determine an appropriate therapy to treat arrhythmia conditions affecting the heart 330. The cardiac therapy may include pacing therapy controlled by the pacemaker 322 to treat cardiac rhythms that are too slow. The pacemaker 322 controls the delivery of periodic low energy pacing pulses to ensure that the periodic contractions of the heart are maintained at a hemodynamically sufficient rate.
The cardiac therapy may also include therapy to terminate tachyarrhythmia, wherein the heart rate is too fast. The arrhythmia detector/therapy unit 324 analyzes cardiac signals received from the cardiac signal detector 350 to recognize tachyarrhythmias including atrial or ventricular tachycardia or fibrillation. The arrhythmia detector/therapy unit 324 recognizes cardiac signals indicative of tachyarrhythmia and delivers high energy stimulations to the heart 330 through the implanted electrodes 331 to terminate the arrhythmias.
Various input devices, including implantable sensors 381, patient-external sensors 382, patient input devices 384, and information systems 383 may be coupled to the CRM 300. These devices 381, 382, 383, 384 may be used to provide information about physiological and/or non-physiological conditions affecting the patient relevant to sleep quality, such as the representative set of patient conditions listed in Table 1 above.
The CRM 300 includes signal detection circuitry 360 for receiving and processing signals from the various sensors and input devices 381, 382, 384, 383. As previously discussed, the signal detection circuitry 360 may include signal processing circuitry configured to amplify, digitize, or otherwise process signals representing the sensed sleep quality conditions. In the illustrated implementation, the patient input devices 384, patient-external sensors 382, and information systems 383 are wirelessly coupled to the CRM 300. The patient-internal sensors 381 may be coupled to the CRM 300 through leads, through a wireless link, or integrated within or on the housing of the CRM 300 (e.g., integral accelerometer).
In one embodiment, the sleep quality data system 305 incorporated within the CRM 300 collects data from cardiac electrodes 331, patient-internal sensors 381, patient-external sensors 382, patient input devices 384, and information systems 383 and stores the collected data in memory. The sleep quality data system may transmit the collected data to a separate device, such as the CRM programmer 315 or other device, periodically as required or desired.
In another embodiment, the CRM sleep quality data system 305 may perform further processing and/or evaluation of the sleep quality data. For this purpose, the CRM sleep quality data system 305 may include a sleep quality analysis unit 340 coupled to the signal detector 360. The sleep quality analysis unit 340 may include one or more components for evaluating the patient's sleep quality. For example, the sleep quality analysis unit 340 may include sleep detection circuitry 341, disordered breathing detection circuitry 342, abnormal nocturnal movement detection circuitry 344, and a sleep quality processor 343, as previously described in connection with
The cardiac therapy module 320, signal detector 360, and sleep quality analysis unit 340 operate in cooperation with a memory unit 370. The memory unit 370 may store parameters associated with cardiac therapy in addition to diagnostic or other data related to cardiac functioning and sleep quality. A communication unit 310 located within the CRM 300 may be used to transmit programming information and collected data from the CRM 300 to an external device such as a programmer 315.
Sleep quality assessment involves a reliable method for discriminating between a state of sleep and a state of wakefulness. One method of detecting sleep involves comparing one or more detected physiological conditions to thresholds indicative of sleep. When the detected conditions are consistent with thresholds indicating sleep, then sleep onset is declared. For example, decreased patient activity is a condition associated with sleep. When the patient's activity falls below a predetermined threshold, the system declares the onset of sleep. When the patient's activity rises above the threshold, the system declares the end of sleep. In a similar manner, a number of patient conditions, such as heart rate, respiration rate, brain wave activity, etc., may be compared individually or collectively compared to thresholds or other indices to detect sleep.
An enhanced method of sleep detection is described in commonly owned U.S. Pat. No. 7,189,204, which is incorporated herein by reference. The method involves adjusting a sleep threshold associated with a first patient condition using a second patient condition. The first patient condition is compared to the adjusted threshold to determine if the patient is asleep or awake.
According to embodiments of the invention, a first sleep-related condition detected using a sleep detection sensor 401 is compared to a sleep threshold for detecting the onset and termination of sleep. A second sleep-related condition, detected using a threshold adjustment sensor 402, is used to adjust the sleep threshold. Although the example described herein involves one sleep detection sensor 401 and one threshold adjustment sensor 402, any number of thresholds or other indices corresponding to a number of sleep detection sensors may be used. Furthermore, conditions detected using any number of adjustment sensors may be used to adjust the thresholds or indices of a plurality of sleep detection signals. Additional sleep-related signals derived from one or more confirmation sensors 403 may optionally be used to confirm the onset or termination of the sleep condition.
Signals derived from the sensors 401, 402, 403 are received by a sensor driver/detection circuitry 410 that may include, for example, amplifiers, signal processing circuitry, and/or A/D conversion circuitry for processing each sensor signal. The sensor driver/detection system 410 may further include sensor drive circuitry required to activate the sensors 401, 402, 403.
The sensor signal detection system 410 is coupled to a sleep detector 430. The sleep detector 430 is configured to compare the level of a first sleep-related condition detected using the sleep detection sensor 401 to a sleep threshold adjusted by a second sleep-related condition detected using the threshold adjustment sensor 402. A determination of sleep onset or sleep termination may be made by the sleep detector 430 based on the comparison. The onset or termination of sleep may optionally be confirmed using patient conditions derived using a sleep confirmation sensor 403.
First and second sleep-related conditions are detected 510, 520. The first and the second sleep-related conditions may be detected using sensors implanted in the patient, attached externally to the patient or located remote from the patient, for example, as previously described in connection with
The sleep threshold established for the first sleep-related condition is adjusted using the second sleep-related condition 530. For example, if the second sleep-related condition indicates a high level of activity that is incompatible with a sleep state, the sleep threshold of the first sleep-related condition may be adjusted downward to require sensing a decreased level of the first sleep-related condition before a sleep condition is detected.
If the first sleep-related condition is consistent with sleep according to the adjusted sleep threshold 540, sleep is detected 550. If the first sleep-related condition is not consistent with sleep using the adjusted sleep threshold, the first and the second sleep-related conditions continue to be detected 510, 520 and the threshold adjusted 530 until sleep is detected 550.
The flow chart of
The activity condition of the patient is monitored 620 using an accelerometer that may be incorporated in an implantable cardiac rhythm management system as described in connection with
In this embodiment, the patient's activity represents the sleep detection condition and is compared to the sleep threshold. The patient's MV is used as the threshold adjustment condition to adjust the sleep threshold. In addition, in this example, the patient's heart rate is monitored 630 and used to provide a sleep confirmation condition.
The sleep threshold adjustment is accomplished using the patient's MV condition to adjust the activity sleep threshold. If the patient's MV condition is low relative to an expected MV level associated with sleep, the activity sleep threshold is increased. Similarly, if the patient's MV level is high relative to an expected MV level associated with sleep, the activity sleep threshold is decreased. Thus, when the patient's MV level is high, less activity is required to make the determination that the patient is sleeping. Conversely when the patient's MV level is relatively low, a higher activity level may result in detection of sleep. The use of two sleep-related conditions to determine the patient's sleep state enhances the accuracy of sleep detection over previous methods.
Various signal processing techniques may be employed to process the raw sensor signals. For example, a moving average of a plurality of samples of the sensor signals may be calculated. Furthermore, the sensor signals may be amplified, filtered, digitized or otherwise processed.
If the MV level is high 635 relative to an expected MV level associated with sleep, the activity sleep threshold is decreased 640. If the MV level is low 635 relative to an expected MV level associated with sleep, the activity sleep threshold is increased 645.
If the patient's activity level is less than or equal to the adjusted sleep threshold 650, and if the patient is currently in a sleep state 665, then the patient's heart rate is checked 680 to confirm that the patient is asleep. If the patient's heart rate is compatible with sleep 680, then sleep onset is determined 690. If the patient's heart rate is incompatible with sleep, then the patient's sleep-related conditions continue to be monitored.
If the patient's activity level is less than or equal to the adjusted sleep threshold 650 and if the patient is currently in a sleep state 665, then a continuing sleep state is determined and the patient's sleep-related conditions continue to be monitored for sleep termination to occur.
If the patient's activity level is greater than the adjusted sleep threshold 650 and the patient is not currently in a sleep state 660, then the patient's sleep-related conditions continue to be monitored until sleep onset is detected 690. If the activity level is greater than the adjusted sleep threshold 650 and the patient is currently in a sleep state 660, then sleep termination is detected 670.
The graphs of
Additional sleep-related conditions may be sensed and used to improve the sleep detection method described above. For example, a posture sensor may be used to detect the posture of the patient and used to confirm sleep. If the posture sensor signal indicates an upright posture, then the posture sensor signal may be used to override a determination of sleep using the sleep detection and threshold adjustment conditions. Other conditions may also be used in connection with sleep determination or confirmation, including the representative set of sleep-related conditions indicated above. In another example, a proximity to bed sensor may be used alone or in combination with a posture sensor to detect that the patient is in bed and is lying down.
A sleep detection system may detect sleep onset, termination, arousals as well as the sleep stages, including REM and non-REM sleep. REM sleep may be discriminated from NREM sleep, for example, by examining one or more signals indicative of REM, e.g., muscle atonia, rapid eye movements, or EEG signals. Methods and systems for detecting REM sleep that are particularly useful for patients with implantable devices are discussed in commonly owned U.S. Publication No. 2005/0043652 and incorporated herein by reference. Various conditions indicative of sleep state may be detected using sensors, e.g., electroencephalogram (EEG), electrooculogram (EOG), or electromyogram (EMG) sensors, coupled through wired or wireless connections to the sleep detection circuitry. The sleep detection circuitry may analyze the various patient conditions sensed by the sensors to track the patient's sleep through various sleep states, including REM and NREM stages.
Returning to
In one embodiment, detection of disordered breathing, including, for example, sleep apnea and hypopnea, involves defining and examining a number of respiratory cycle intervals.
Detection of sleep apnea and severe sleep apnea according to embodiments of the invention is illustrated in
Hypopnea is a condition of disordered breathing characterized by abnormally shallow breathing.
According to an embodiment of the invention, hypopnea is detected by comparing a patient's respiratory tidal volume to a hypopnea tidal volume threshold. The tidal volume for each respiration cycle may be derived from transthoracic impedance measurements. The hypopnea tidal volume threshold may be established using clinical results providing a representative tidal volume and duration for hypopnea events. In one configuration, hypopnea is detected when an average of the patient's respiratory tidal volume taken over a selected time interval falls below the hypopnea tidal volume threshold.
The patient's transthoracic impedance is detected 1505. If the transthoracic impedance exceeds 1510 the inspiration threshold, the beginning of an inspiration interval is detected 1515. If the transthoracic impedance remains below 1510 the inspiration threshold, then the impedance signal is checked 1505 periodically until inspiration 1515 occurs.
During the inspiration interval, the patient's transthoracic impedance is monitored until a maximum value of the transthoracic impedance is detected 1520. Detection of the maximum value signals an end of the inspiration period and a beginning of an expiration period 1535.
The expiration interval is characterized by decreasing transthoracic impedance. When the transthoracic impedance falls below 1540 the expiration threshold, a non-breathing interval is detected 1555.
If the transthoracic impedance does not exceed 1560 the inspiration threshold within a first predetermined interval 1565, denoted the sleep apnea interval, then a condition of sleep apnea is detected 1570. Severe sleep apnea is detected 1580 if the non-breathing period extends beyond a second predetermined interval 1575, denoted the severe sleep apnea interval.
When the transthoracic impedance exceeds 1560 the inspiration threshold, the tidal volume from the peak-to-peak transthoracic impedance is calculated 1585. The peak-to-peak transthoracic impedance provides a value proportional to the tidal volume of the respiration cycle. This value is compared 1590 to a hypopnea tidal volume threshold. If the peak-to-peak transthoracic impedance is consistent with 1590 the hypopnea tidal volume threshold for a predetermined time 1592, then a hypopnea cycle is detected 1595.
Additional sensors, such as motion sensors and/or posture sensors, may be used to confirm or verify the detection of a sleep apnea or hypopnea episode. The additional sensors may be employed to prevent false or missed detections of sleep apnea or hypopnea due to posture and/or motion related artifacts.
Another embodiment of the invention involves classifying respiration patterns as disordered breathing episodes based on the breath intervals and/or tidal volumes of one or more respiration cycles within the respiration patterns. According to this embodiment, the duration and tidal volumes associated with a respiration pattern are compared to duration and tidal volume thresholds. The respiration pattern may be determined to represent a disordered breathing episode based on the comparison.
According to this embodiment, a breath interval 1630 is established for each respiration cycle. A breath interval represents the interval of time between successive breaths, as illustrated in
Detection of disordered breathing, in accordance with methods of the invention, involves the establishment of a duration threshold and a tidal volume threshold. If a breath interval exceeds the duration threshold, an apnea event is detected. Detection of sleep apnea, in accordance with this embodiment, is illustrated in the graph of
Hypopnea may be detected using a duration threshold and a tidal volume threshold. A hypopnea event represents a period of shallow breathing greater than the duration threshold. Each respiration cycle in a hypopnea event is characterized by a tidal volume less than the tidal volume threshold. Further, the decreased tidal volume cycles persist longer than the duration threshold.
A hypopnea detection approach, in accordance with embodiments of the invention, is illustrated in
As illustrated in
As illustrated in
The patient's respiration cycles are determined, for example, using transthoracic impedance signals. Each breath 1910 is characterized by a breath interval, i.e., the interval of time between two impedance signal maxima and a tidal volume (TV). If a breath interval exceeds 1915 the duration threshold, then the respiration pattern is consistent with an apnea event, and an apnea event trigger is turned on 1920. If the tidal volume of the breath interval exceeds 1925 the tidal volume threshold, then the breathing pattern is characterized by two respiration cycles of normal volume separated by a non-breathing interval. This pattern represents a purely apneic disordered breathing event, and apnea is detected 1930. Because the final breath of the breath interval was normal, the apnea event trigger is turned off 1932, signaling the end of the disordered breathing episode. However, if the tidal volume of the breath interval does not exceed 1925 the tidal volume threshold, the disordered breathing period is continuing and the next breath is checked 1910.
If the breath interval does not exceed 1915 the duration threshold, then the tidal volume of the breath is checked 1935. If the tidal volume does not exceed 1935 the tidal volume threshold, the breathing pattern is consistent with a hypopnea cycle and a hypopnea event trigger is set on 1940. If the tidal volume exceeds the tidal volume threshold, then the breath is normal.
If a period of disordered breathing is in progress, detection of a normal breath signals the end of the disordered breathing. If disordered breathing was previously detected 1945, and if the disordered breathing event duration has not exceeded 1950 the duration threshold, and the current breath is normal, then no disordered breathing event is detected 1955. If disordered breathing was previously detected 1945, and if the disordered breathing event duration has extended for a period of time exceeding 1950 the duration threshold, and the current breath is normal, then the disordered breathing trigger is turned off 1960. In this situation, the duration of the disordered breathing episode was of sufficient duration to be classified as a disordered breathing episode. If an apnea event was previously triggered 1965, then an apnea event is declared 1970. If a hypopnea was previously triggered 1965, then a hypopnea event is declared 1975.
As previously discussed in connection with
In the implementation illustrated in
In this application, the sleep quality data collection and analysis unit 2020 is configured to track the patient's heart rate, heart rate variability, minute ventilation, respiration rate, tidal volume, posture, proximity to bed, brain activity, eye movements, jaw movements and leg movements. At periodic intervals, the system samples signals from the sensors and stores data regarding the detected conditions in memory circuitry within the sleep quality data collection and analysis unit 2020. The sleep quality data collection and analysis unit 2020 may additionally access an external input unit 2030 to detect patient reported conditions, for example, recent tobacco and medication use by the patient. Further, the sleep quality data collection and analysis unit 2020 may monitor conditions using one or more external sensors. In the illustrated example, a thermometer 2035 is coupled through the external programmer 2030 and a pollution website 2040 is accessible to the sleep quality data collection and analysis unit 2020 through the internet 2050.
The sleep quality data collection and analysis unit 2020 may operate to acquire data during periods of both sleep and wakefulness. It may be beneficial, for example, to track changes in particular conditions measured during periods of wakefulness that are associated with sleep disordered breathing. For example, some patients who suffer from sleep apnea experience changes in heart rate variability, blood pressure variability, and/or sympathetic nerve activity during periods of wakefulness. Detection and analysis of the physiological changes attributable to sleep disorders and measurable during the time the patient is awake provides a more complete picture of sleep quality.
In another example, the patient's sleep quality may be evaluated by determining the patient's activity level while the patient is awake. The activity level of the patient during the day may provide important information regarding the patient's sleep quality. For example, if the patient is very inactive during periods of wakefulness, this may indicate that the patient's sleep is of inadequate quality or duration. Such information may also be used in connection with assessing the efficacy of a particular sleep disorder therapy and/or adjusting the patient's sleep disorder therapy. Methods and systems for determining the patient's activity level and generally assessing the well-being of a patient are described in commonly owned U.S. Pat. No. 6,021,351 which is incorporated herein by reference.
The analysis unit 2020 may calculate one or more sleep quality metrics quantifying the patient's sleep quality. A representative set of the sleep quality metrics include, for example, sleep efficiency, sleep fragmentation, number of arousals per hour, denoted the arousal index (AI).
The analysis unit 2020 may also compute one or more metrics quantifying the patient's disordered breathing, such as the apnea hypopnea index (AHI) providing the number of apneas and hypopneas per hour, and the percent time in periodic breathing (% PB).
Further, metrics associated with sleep movement disorders may also be determined by the analysis unit 2020. Such metrics may include, for example, a general sleep movement disorder index (MDI) representing the number of abnormal movements arising from movement disorders such as restless leg syndrome, periodic limb movement disorder and bruxism per hour. In addition, specific indices may be calculated for each type of movement disorder, e.g., a bruxism index (BI) characterizing the number of jaw movements per hour, a RLS index (RLSI) characterizing the number of restless leg syndrome episodes per hour, and a PLM index (PLMI) characterizing the number of periodic limb movements experienced by the patient per hour.
In addition, percentage of sleep time during which the patient experiences movement disorders (% MD) may be calculated. Specific metrics relating to the percentage of time during which the patient experiences bruxism (% B), restless leg syndrome (% RLS), and periodic leg movement disorder (% PLMD) may also be determined.
Further, sleep summary metrics may be computed, either directly from the collected patient condition data, or by combining the above-listed sleep quality and sleep disorder metrics. In one embodiment, a composite sleep disordered respiration metric (SDRM) may be computed by combining the apnea hypopnea index AHI and the arousal index AI. The composite sleep disordered respiration metric (SDRM) may be computed as a linear combination of the AHI and AI as follows:
SDRM=c1*AHI+c2*AI [1]
where c1 and c2 are constants chosen to balance the relative contributions of respiratory and arousal effects on sleep disturbance. The AHI may be monitored by performing disordered breathing detection based on transthoracic impedance measurements as previously described. The AI may be estimated, for example, by monitoring the patient activity, minute ventilation, and posture sensors for body motion indicating sleep termination or arousal. A more sensitive measure of arousal may be made using EEG signals. In this implementation, the constant c2 may be adjusted to reflect the increased sensitivity to arousal.
In another embodiment, an undisturbed respiration sleep time (URST) or undisturbed respiration sleep efficiency (URSE) may be computed based on the amount of time the patient spends asleep in bed without respiratory disturbance.
The URST or URSE metrics may be determined using three parameters: total time in bed (TIB), total time asleep (TA), and combined sleep time duration in disturbed respiration (STDR). Time in bed may be determined by a combination of posture sensing and sensing the proximity of the patient to bed. The posture condition of the patient may determined, for example, using an implantable multiaxis accelerometer sensor.
The patient's total time in bed (TIB) may be determined using a proximity to bed sensor. The proximity to bed sensor may use a receiver in the sleep quality data collection and analysis unit 2020 for receiving signals transmitted from a beacon 2070 located at the patient's bed 2060. If the proximity to bed receiver detects a signal of sufficient strength from the proximity to bed beacon 2070, then the receiver detects that the patient is in bed 2060.
Total time asleep (TA) may be determined using the sleep detection method described in more detail above. The total sleep time in disturbed respiration (STDR) may be determined, for example, based on detection of sleep and disordered breathing using the sleep and disordered breathing detection methods described above.
The patient's undisturbed respiration sleep time (URST) is calculated as:
URST=TA−STDR [2]
where TA=total time asleep and STDR=sleep time in disturbed breathing.
The undisturbed respiration sleep efficiency (USE) in percent is calculated
URSE=100*URST/TIB [3]
where URST=undisturbed respiration sleep time and TIB=total time in bed.
Similar metrics may be calculated for movement disorders generally, or for specific movement disorders, e.g., RLS, PLMD, or bruxism. For example, the composite RLS, PLMD, and bruxism metrics, RLSM, PLMDM, and BM, respectively, may be calculated using equations similar in form to equation 1 above:
RLSM=c1*RLSI+c2*AI [4]
where RLSI=number of restless leg movement syndrome episodes per hour, AI=number of arousals per hour, and c1 and c2 are constants chosen to balance the relative contributions of abnormal movement and arousal effects on sleep disturbance.
PLMDM=c1*PLMDI+c2*AI [5]
where PLMDI=number of periodic leg movement syndrome episodes per hour, AI=number of arousals per hour, and c1 and c2 are constants chosen to balance the relative contributions of abnormal movement and arousal effects on sleep disturbance.
BM=c1*BMI+c2*AI [6]
where BMI=number of bruxism movement episodes per hour, AI=number of arousals per hour, and c1 and c2 are constants chosen to balance the relative contributions of abnormal movement and arousal effects on sleep disturbance.
The patient's undisturbed movement sleep time (UMST) and undisturbed movement sleep efficiency (UMSE) may be calculated for each movement related disorder separately or in combination using equations similar in form to equations 2 and 3, above.
In addition, a composite sleep disorder index SDI quantifying the combined effect of both respiratory and movement disorders may be computed by combining the apnea hypopnea index (AHI), the movement disorder index (MDI), and the arousal index (AI).
A sleep disturbance index (SDI) may be computed as a linear combination of the AHI, and the combined disorder index DIc. The combined disorder index may include both abnormal breathing and movement components. For example, the sleep disturbance index SDI is characterizable by the equation:
SDI=c4*DIc+c3*AI, [7]
where DIc is a combined disorder index of the form:
DIc=c41*DI1+c42*DI2 [7a]
In equation 7, c4 and c3 are constants chosen to balance the relative contributions of the combined disorder and arousal effects, respectively. The disorder index, DIc, may be used to characterize the effects of one or more sleep disorders, including, e.g., disorders associated with disturbed respiration and/or abnormal movements. The combined disorder index may represent only one disorder index, or may be a linear combination of two or more sleep disorder indices, e.g., the apnea/hypopnea index (AHI) and the abnormal movement disorder index (MDI). The constants C41 and c42 may be used as weighting factors associated with particular disorder indices.
The patient's undisturbed sleep time (UST) may be calculated:
UST=TA−STSD [8]
where TA=total time asleep and STSD=sleep time spent in sleep disorders.
The undisturbed sleep efficiency (USE) in percent may be calculated:
USE=100*UST/TIB [9]
where UST=undisturbed sleep time and TIB=total time in bed.
Sleep quality metrics, such as those described above, or other metrics, may be acquired and analyzed using the sleep quality data collection and analysis unit 2020. Sleep quality metrics, in addition to raw or processed data based on physiological and non-physiological conditions may determined periodically, e.g., daily, and stored or transmitted to another device. Such data can be presented to the patient's health care professional on a real-time basis, or as a long-term, e.g., month long or year long, trend of daily measurements.
The health care professional may access the data during clinic visits via programmer interrogation of the implanted device, through occasional or periodic trans-telephonic device interrogations, or through an automatic or “on-demand” basis in the context of an advanced patient management system. The health care professionals may use the sleep quality indicator trends alone or in conjunction with other device-gathered or clinical data to diagnose disorders and/or adjust the patient's device or medical therapy as needed to improve the patient's quality of sleep.
The present invention provides diagnostic, monitoring, and evaluation capabilities relating to sleep quality and may be particularly valuable in the context of an advanced patient management system. Undiagnosed sleep disorders can lead to increased morbidity and mortality, such as those arising from various respiratory and cardiovascular consequences. Routine monitoring of patient sleep quality may lead to improved diagnosis and treatment of these syndromes and their associated co-morbidities. The invention may provide less obtrusive sleep quality monitoring, particularly and is suited for patients having an implanted device. The present invention serves to improve diagnosis of sleep disorders by reducing the inconveniences, unnatural sleep environment issues, and expenses associated with sleep clinic polysomnogram studies.
The following commonly owned U.S. patents applications, some of which have been identified above, are hereby incorporated by reference in their respective entireties: U.S. patent application Ser. No. 10/309,770, filed Dec. 4, 2002, U.S. patent application Ser. No. 10/309,771, filed Dec. 4, 2002, U.S. patent application entitled “Prediction of Disordered Breathing,” identified by and concurrently filed with this patent application, U.S. patent application entitled “Adaptive Therapy for Disordered Breathing,” identified by and filed concurrently with this patent application, U.S. patent application entitled “Prediction of Disordered Breathing,” identified by and filed concurrently with this patent application, and U.S. patent application entitled “Therapy Triggered by Prediction of Disordered Breathing,” identified by and filed concurrently with this patent application.
Various modifications and additions can be made to the preferred embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof.
Number | Name | Date | Kind |
---|---|---|---|
3650277 | Sjostrand et al. | Mar 1972 | A |
4091818 | Brownlee et al. | May 1978 | A |
4312355 | Funke | Jan 1982 | A |
4312734 | Nichols | Jan 1982 | A |
4365636 | Barker | Dec 1982 | A |
4390405 | Hahn et al. | Jun 1983 | A |
4414982 | Durkan | Nov 1983 | A |
4648407 | Sackner | Mar 1987 | A |
4702253 | Nappholz et al. | Oct 1987 | A |
4721110 | Lampadius | Jan 1988 | A |
4777962 | Watson et al. | Oct 1988 | A |
4784162 | Ricks et al. | Nov 1988 | A |
4791931 | Slate | Dec 1988 | A |
4802485 | Bowers et al. | Feb 1989 | A |
4807629 | Baudino et al. | Feb 1989 | A |
4813427 | Schlaefke et al. | Mar 1989 | A |
4827943 | Bornn et al. | May 1989 | A |
4830008 | Meer | May 1989 | A |
4836219 | Hobson et al. | Jun 1989 | A |
4856524 | Baker, Jr. | Aug 1989 | A |
4860766 | Sackner | Aug 1989 | A |
4875477 | Waschke et al. | Oct 1989 | A |
4886064 | Strandberg | Dec 1989 | A |
4953551 | Mehra et al. | Sep 1990 | A |
4958632 | Duggan | Sep 1990 | A |
4961423 | Canducci | Oct 1990 | A |
4972842 | Korten et al. | Nov 1990 | A |
4982738 | Griebel | Jan 1991 | A |
5003975 | Hafelfinger et al. | Apr 1991 | A |
5010888 | Jadvar et al. | Apr 1991 | A |
5024222 | Thacker | Jun 1991 | A |
5047930 | Martens et al. | Sep 1991 | A |
5063927 | Webb et al. | Nov 1991 | A |
5074301 | Gill | Dec 1991 | A |
5101831 | Koyama et al. | Apr 1992 | A |
5111815 | Mower | May 1992 | A |
5123425 | Shannon, Jr. et al. | Jun 1992 | A |
5133353 | Hauser | Jul 1992 | A |
5146918 | Kallok et al. | Sep 1992 | A |
5156157 | Valenta, Jr. et al. | Oct 1992 | A |
5158089 | Swezey et al. | Oct 1992 | A |
5170784 | Ramon et al. | Dec 1992 | A |
5174287 | Kallok et al. | Dec 1992 | A |
5179945 | Van Hofwegen et al. | Jan 1993 | A |
5183038 | Hoffman et al. | Feb 1993 | A |
5188106 | Nappholz et al. | Feb 1993 | A |
5190035 | Salo et al. | Mar 1993 | A |
5199424 | Sullivan et al. | Apr 1993 | A |
5199428 | Obel et al. | Apr 1993 | A |
5203326 | Collins | Apr 1993 | A |
5209229 | Gilli | May 1993 | A |
5211173 | Kallok et al. | May 1993 | A |
5215082 | Kallok et al. | Jun 1993 | A |
5233983 | Markowitz | Aug 1993 | A |
5243979 | Stein et al. | Sep 1993 | A |
5243980 | Mehra | Sep 1993 | A |
5245995 | Sullivan et al. | Sep 1993 | A |
5259373 | Gruenke et al. | Nov 1993 | A |
5261400 | Bardy | Nov 1993 | A |
5275159 | Griebel | Jan 1994 | A |
5280791 | Lavie | Jan 1994 | A |
5292338 | Bardy | Mar 1994 | A |
5299118 | Martens et al. | Mar 1994 | A |
5300106 | Dahl et al. | Apr 1994 | A |
5306293 | Zacouto | Apr 1994 | A |
5314430 | Bardy | May 1994 | A |
5314459 | Swanson et al. | May 1994 | A |
5318592 | Schaldach | Jun 1994 | A |
5318593 | Duggan | Jun 1994 | A |
5318594 | Limousin et al. | Jun 1994 | A |
5318597 | Hauck et al. | Jun 1994 | A |
5330505 | Cohen | Jul 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5353788 | Miles | Oct 1994 | A |
5356425 | Bardy et al. | Oct 1994 | A |
5363842 | Mishelevich et al. | Nov 1994 | A |
5372606 | Lang et al. | Dec 1994 | A |
5376103 | Anderson et al. | Dec 1994 | A |
5376106 | Stahmann et al. | Dec 1994 | A |
5377671 | Biondi et al. | Jan 1995 | A |
5391187 | Freeman | Feb 1995 | A |
5398682 | Lynn | Mar 1995 | A |
5404877 | Nolan et al. | Apr 1995 | A |
5411525 | Swanson et al. | May 1995 | A |
5411531 | Hill et al. | May 1995 | A |
5411539 | Neisz | May 1995 | A |
5417717 | Salo et al. | May 1995 | A |
5437285 | Verrier et al. | Aug 1995 | A |
5439482 | Adams et al. | Aug 1995 | A |
5441518 | Adams et al. | Aug 1995 | A |
5466245 | Heemels et al. | Nov 1995 | A |
5468254 | Hahn et al. | Nov 1995 | A |
5476485 | Weinberg et al. | Dec 1995 | A |
5483969 | Testerman et al. | Jan 1996 | A |
5485851 | Erickson | Jan 1996 | A |
5487755 | Snell et al. | Jan 1996 | A |
5490502 | Rapoport et al. | Feb 1996 | A |
5507784 | Hill et al. | Apr 1996 | A |
5517983 | Deighan et al. | May 1996 | A |
5520176 | Cohen | May 1996 | A |
5520191 | Karlsson et al. | May 1996 | A |
5522382 | Sullivan et al. | Jun 1996 | A |
5522854 | Ideker et al. | Jun 1996 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5527345 | Infinger | Jun 1996 | A |
5531779 | Dahl et al. | Jul 1996 | A |
5540732 | Testerman | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5554177 | Kieval | Sep 1996 | A |
5578061 | Stroetmann et al. | Nov 1996 | A |
5590648 | Mitchell et al. | Jan 1997 | A |
5591216 | Testerman et al. | Jan 1997 | A |
5593431 | Sheldon | Jan 1997 | A |
5601607 | Adams | Feb 1997 | A |
5603331 | Heemels et al. | Feb 1997 | A |
5605151 | Lynn | Feb 1997 | A |
5606969 | Butler et al. | Mar 1997 | A |
5607385 | Francischelli et al. | Mar 1997 | A |
5620466 | Haefner et al. | Apr 1997 | A |
5622178 | Gilham | Apr 1997 | A |
5626151 | Linden | May 1997 | A |
5632281 | Rayburn | May 1997 | A |
5634938 | Swanson et al. | Jun 1997 | A |
5641326 | Adams | Jun 1997 | A |
5645570 | Corbucci | Jul 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5662688 | Haefner et al. | Sep 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5693000 | Crosby et al. | Dec 1997 | A |
5697951 | Harpstead et al. | Dec 1997 | A |
5697953 | Kroll et al. | Dec 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5701894 | Cherry et al. | Dec 1997 | A |
5704345 | Berthon-Jones | Jan 1998 | A |
5704365 | Albrecht et al. | Jan 1998 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5713355 | Richardson et al. | Feb 1998 | A |
5713933 | Condie et al. | Feb 1998 | A |
5715812 | Deighan et al. | Feb 1998 | A |
5716377 | Rise et al. | Feb 1998 | A |
5720771 | Snell | Feb 1998 | A |
5724984 | Arnold et al. | Mar 1998 | A |
5740797 | Dickson | Apr 1998 | A |
5782883 | Kroll et al. | Jul 1998 | A |
5792188 | Starkweather et al. | Aug 1998 | A |
5794615 | Estes | Aug 1998 | A |
5797967 | KenKnight | Aug 1998 | A |
5800470 | Stein et al. | Sep 1998 | A |
5802188 | McDonough | Sep 1998 | A |
5814079 | Kieval | Sep 1998 | A |
5826579 | Remmers et al. | Oct 1998 | A |
5827326 | Kroll et al. | Oct 1998 | A |
5839430 | Cama | Nov 1998 | A |
5844680 | Sperling | Dec 1998 | A |
5860918 | Schradi et al. | Jan 1999 | A |
5861011 | Stoop | Jan 1999 | A |
5869970 | Palm et al. | Feb 1999 | A |
5876353 | Riff | Mar 1999 | A |
5891023 | Lynn | Apr 1999 | A |
5895414 | Sanchez-Zambrano | Apr 1999 | A |
5902250 | Verrier et al. | May 1999 | A |
5911218 | DiMarco | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5919141 | Money et al. | Jul 1999 | A |
5957861 | Combs et al. | Sep 1999 | A |
5957956 | Kroll et al. | Sep 1999 | A |
5961446 | Beller et al. | Oct 1999 | A |
5961450 | Merchant et al. | Oct 1999 | A |
5964788 | Greenhut | Oct 1999 | A |
5970975 | Estes et al. | Oct 1999 | A |
5974340 | Kadhiresan | Oct 1999 | A |
5974349 | Levine | Oct 1999 | A |
5981011 | Overcash et al. | Nov 1999 | A |
5997526 | Giba et al. | Dec 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6015388 | Sackner et al. | Jan 2000 | A |
6021351 | Kadhiresan et al. | Feb 2000 | A |
6044297 | Sheldon et al. | Mar 2000 | A |
6045513 | Stone et al. | Apr 2000 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6050940 | Braun et al. | Apr 2000 | A |
6058331 | King | May 2000 | A |
6059725 | Steinschneider | May 2000 | A |
6064910 | Andersson et al. | May 2000 | A |
6073048 | Kieval et al. | Jun 2000 | A |
6091986 | Keimel | Jul 2000 | A |
6099479 | Christopherson et al. | Aug 2000 | A |
6105575 | Estes et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6117092 | Weinstein et al. | Sep 2000 | A |
6120441 | Griebel | Sep 2000 | A |
6134470 | Hartlaub | Oct 2000 | A |
6141590 | Renirie et al. | Oct 2000 | A |
6144866 | Miesel et al. | Nov 2000 | A |
6148230 | KenKnight | Nov 2000 | A |
6148233 | Owen et al. | Nov 2000 | A |
6148814 | Clemmer et al. | Nov 2000 | A |
6155976 | Sackner et al. | Dec 2000 | A |
6161042 | Hartley et al. | Dec 2000 | A |
6168568 | Gavriely | Jan 2001 | B1 |
6178349 | Kieval | Jan 2001 | B1 |
6181961 | Prass | Jan 2001 | B1 |
6181966 | Nigam | Jan 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6205357 | Ideker et al. | Mar 2001 | B1 |
6212435 | Lattner et al. | Apr 2001 | B1 |
6227072 | Ritchey et al. | May 2001 | B1 |
6236873 | Holmström | May 2001 | B1 |
6240314 | Plicchi et al. | May 2001 | B1 |
6240316 | Richmond et al. | May 2001 | B1 |
6253103 | Baura | Jun 2001 | B1 |
6261238 | Gavriely | Jul 2001 | B1 |
6263244 | Mann et al. | Jul 2001 | B1 |
6264606 | Ekwall et al. | Jul 2001 | B1 |
6269269 | Ottenhoff et al. | Jul 2001 | B1 |
6270457 | Bardy | Aug 2001 | B1 |
6275727 | Hopper et al. | Aug 2001 | B1 |
6280462 | Hauser et al. | Aug 2001 | B1 |
6286508 | Remmers et al. | Sep 2001 | B1 |
6287264 | Hoffman | Sep 2001 | B1 |
6292693 | Darvish et al. | Sep 2001 | B1 |
6292695 | Webster et al. | Sep 2001 | B1 |
6299581 | Rapoport et al. | Oct 2001 | B1 |
6303270 | Flaim et al. | Oct 2001 | B1 |
6306088 | Krausman | Oct 2001 | B1 |
6310085 | Willis | Oct 2001 | B1 |
6312378 | Bardy | Nov 2001 | B1 |
6314319 | Kroll et al. | Nov 2001 | B1 |
6317627 | Ennen | Nov 2001 | B1 |
6327499 | Alt | Dec 2001 | B1 |
6331536 | Radulovacki et al. | Dec 2001 | B1 |
6336903 | Bardy | Jan 2002 | B1 |
6351670 | Kroll | Feb 2002 | B1 |
6357444 | Parker | Mar 2002 | B1 |
6360127 | Ding et al. | Mar 2002 | B1 |
6361494 | Lindenthaler | Mar 2002 | B1 |
6361522 | Scheiner et al. | Mar 2002 | B1 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6375614 | Braun et al. | Apr 2002 | B1 |
6375623 | Gavriely | Apr 2002 | B1 |
6387907 | Hendricks et al. | May 2002 | B1 |
6397845 | Burton | Jun 2002 | B1 |
6398727 | Bui et al. | Jun 2002 | B1 |
6398728 | Bardy | Jun 2002 | B1 |
6398739 | Sullivan et al. | Jun 2002 | B1 |
6400982 | Sweeney et al. | Jun 2002 | B2 |
6409675 | Turcott | Jun 2002 | B1 |
6411845 | Mower et al. | Jun 2002 | B1 |
6411850 | Kay et al. | Jun 2002 | B1 |
6414183 | Sakamoto et al. | Jul 2002 | B1 |
6415174 | Bebehani et al. | Jul 2002 | B1 |
6415183 | Scheiner et al. | Jul 2002 | B1 |
6421557 | Meyer | Jul 2002 | B1 |
6431171 | Burton | Aug 2002 | B1 |
6438407 | Ousdigian et al. | Aug 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6442433 | Linberg | Aug 2002 | B1 |
6447459 | Larom | Sep 2002 | B1 |
6449503 | Hsu | Sep 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6450957 | Yoshimi | Sep 2002 | B1 |
6454708 | Ferguson et al. | Sep 2002 | B1 |
6454719 | Greenhut | Sep 2002 | B1 |
6463326 | Hartley et al. | Oct 2002 | B1 |
6467333 | Lewis et al. | Oct 2002 | B2 |
6468219 | Njemanze | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6477420 | Struble et al. | Nov 2002 | B1 |
6487450 | Chen et al. | Nov 2002 | B1 |
6491639 | Turcott | Dec 2002 | B1 |
6493585 | Plicchi et al. | Dec 2002 | B2 |
6496715 | Lee et al. | Dec 2002 | B1 |
6497658 | Roizen et al. | Dec 2002 | B2 |
6505067 | Lee et al. | Jan 2003 | B1 |
6511500 | Rahme | Jan 2003 | B1 |
6512940 | Brabec et al. | Jan 2003 | B1 |
6514218 | Yamamoto | Feb 2003 | B2 |
6522915 | Ceballos et al. | Feb 2003 | B1 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6527729 | Turcott | Mar 2003 | B1 |
6532388 | Hill et al. | Mar 2003 | B1 |
6542774 | Hill et al. | Apr 2003 | B2 |
6544199 | Morris | Apr 2003 | B1 |
6547743 | Brydon | Apr 2003 | B2 |
6564096 | Mest | May 2003 | B2 |
6564106 | Guck et al. | May 2003 | B2 |
6572543 | Christopherson et al. | Jun 2003 | B1 |
6580944 | Katz et al. | Jun 2003 | B1 |
6584351 | Ekwall | Jun 2003 | B1 |
6595927 | Pitts-Crick et al. | Jul 2003 | B2 |
6595928 | Mansy et al. | Jul 2003 | B2 |
6600949 | Turcott | Jul 2003 | B1 |
6606993 | Wiesmann et al. | Aug 2003 | B1 |
6607509 | Bobroff et al. | Aug 2003 | B2 |
6611713 | Schauerte | Aug 2003 | B2 |
6615083 | Kupper | Sep 2003 | B2 |
6618618 | Kalgren et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622046 | Fraley et al. | Sep 2003 | B2 |
6628986 | Mouchawar et al. | Sep 2003 | B1 |
6628987 | Hill et al. | Sep 2003 | B1 |
6641542 | Cho et al. | Nov 2003 | B2 |
6658292 | Kroll et al. | Dec 2003 | B2 |
6662032 | Gavish et al. | Dec 2003 | B1 |
6679250 | Walker et al. | Jan 2004 | B2 |
6694186 | Bardy | Feb 2004 | B2 |
6704590 | Haldeman | Mar 2004 | B2 |
6708058 | Kim et al. | Mar 2004 | B2 |
6723055 | Hoffman | Apr 2004 | B2 |
6731984 | Cho et al. | May 2004 | B2 |
6741885 | Park et al. | May 2004 | B1 |
6748252 | Lynn et al. | Jun 2004 | B2 |
6752765 | Jensen et al. | Jun 2004 | B1 |
6752766 | Kowallik et al. | Jun 2004 | B2 |
6760615 | Ferek-Petric | Jul 2004 | B2 |
6766190 | Ferek-Petric | Jul 2004 | B2 |
6770029 | Iliff | Aug 2004 | B2 |
6773404 | Poezevera et al. | Aug 2004 | B2 |
6786866 | Odagiri et al. | Sep 2004 | B2 |
6799072 | Ries et al. | Sep 2004 | B2 |
6810287 | Zhu et al. | Oct 2004 | B2 |
6811538 | Westbrook et al. | Nov 2004 | B2 |
6830548 | Bonnet et al. | Dec 2004 | B2 |
6850801 | Kieval et al. | Feb 2005 | B2 |
6857428 | Thornton | Feb 2005 | B2 |
6890306 | Poezevera | May 2005 | B2 |
6892095 | Salo | May 2005 | B2 |
6904320 | Park et al. | Jun 2005 | B2 |
6910481 | Kimmel et al. | Jun 2005 | B2 |
6912419 | Hill et al. | Jun 2005 | B2 |
6922589 | Stahmann et al. | Jul 2005 | B2 |
6928324 | Park et al. | Aug 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6959214 | Pape et al. | Oct 2005 | B2 |
6964641 | Cho et al. | Nov 2005 | B2 |
6988498 | Berthon-Jones et al. | Jan 2006 | B2 |
6999817 | Park et al. | Feb 2006 | B2 |
7025729 | de Chazal et al. | Apr 2006 | B2 |
7025730 | Cho et al. | Apr 2006 | B2 |
7027871 | Burnes et al. | Apr 2006 | B2 |
7039468 | Freed et al. | May 2006 | B2 |
7062308 | Jackson | Jun 2006 | B1 |
7081095 | Lynn et al. | Jul 2006 | B2 |
7089936 | Madaus et al. | Aug 2006 | B2 |
7092755 | Florio | Aug 2006 | B2 |
7094207 | Koh | Aug 2006 | B1 |
7110820 | Tcheng et al. | Sep 2006 | B2 |
7115097 | Johnson | Oct 2006 | B2 |
7117036 | Florio | Oct 2006 | B2 |
7127290 | Girouard et al. | Oct 2006 | B2 |
7130687 | Cho et al. | Oct 2006 | B2 |
7136704 | Schulman | Nov 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7179229 | Koh | Feb 2007 | B1 |
7184817 | Zhu et al. | Feb 2007 | B2 |
7189204 | Ni et al. | Mar 2007 | B2 |
7194313 | Libbus | Mar 2007 | B2 |
7204805 | Dean | Apr 2007 | B2 |
7207945 | Bardy | Apr 2007 | B2 |
7212862 | Park et al | May 2007 | B2 |
7218964 | Hill et al. | May 2007 | B2 |
7225013 | Geva et al. | May 2007 | B2 |
7225021 | Park et al. | May 2007 | B1 |
7225809 | Bowen et al. | Jun 2007 | B1 |
7231250 | Band et al. | Jun 2007 | B2 |
7252640 | Ni et al. | Aug 2007 | B2 |
7269459 | Koh | Sep 2007 | B1 |
7277757 | Casavant et al. | Oct 2007 | B2 |
7289854 | Bardy et al. | Oct 2007 | B2 |
7292890 | Whitehurst | Nov 2007 | B2 |
7302295 | Stahmann et al. | Nov 2007 | B2 |
7308311 | Sorensen et al. | Dec 2007 | B2 |
7395115 | Poezevera | Jul 2008 | B2 |
7428468 | Takemura et al. | Sep 2008 | B2 |
7460906 | Libbus | Dec 2008 | B2 |
7481759 | Whitehurst et al. | Jan 2009 | B2 |
7486991 | Libbus et al. | Feb 2009 | B2 |
7509166 | Libbus | Mar 2009 | B2 |
7570997 | Lovett et al. | Aug 2009 | B2 |
7662101 | Lee et al. | Feb 2010 | B2 |
7747323 | Libbus et al. | Jun 2010 | B2 |
20010000346 | Ruton et al. | Apr 2001 | A1 |
20010018547 | Mechlenburg et al. | Aug 2001 | A1 |
20020002327 | Grant et al. | Jan 2002 | A1 |
20020026221 | Hill et al. | Feb 2002 | A1 |
20020026222 | Schauerte et al. | Feb 2002 | A1 |
20020035376 | Bardy et al. | Mar 2002 | A1 |
20020035377 | Bardy et al. | Mar 2002 | A1 |
20020035378 | Bardy et al. | Mar 2002 | A1 |
20020035379 | Bardy et al. | Mar 2002 | A1 |
20020035380 | Rissmann et al. | Mar 2002 | A1 |
20020035381 | Bardy et al. | Mar 2002 | A1 |
20020042629 | Bardy et al. | Apr 2002 | A1 |
20020042630 | Bardy et al. | Apr 2002 | A1 |
20020042634 | Bardy et al. | Apr 2002 | A1 |
20020049475 | Bardy et al. | Apr 2002 | A1 |
20020049476 | Bardy et al. | Apr 2002 | A1 |
20020052636 | Bardy et al. | May 2002 | A1 |
20020058877 | Baumann et al. | May 2002 | A1 |
20020068958 | Bardy et al. | Jun 2002 | A1 |
20020072773 | Bardy et al. | Jun 2002 | A1 |
20020072776 | Osorio et al. | Jun 2002 | A1 |
20020082652 | Wentkowski et al. | Jun 2002 | A1 |
20020082658 | Heinrich et al. | Jun 2002 | A1 |
20020085741 | Shimizu | Jul 2002 | A1 |
20020091414 | Bardy et al. | Jul 2002 | A1 |
20020095184 | Bardy et al. | Jul 2002 | A1 |
20020103510 | Bardy et al. | Aug 2002 | A1 |
20020107544 | Ostroff et al. | Aug 2002 | A1 |
20020107545 | Rissmann et al. | Aug 2002 | A1 |
20020107546 | Ostroff et al. | Aug 2002 | A1 |
20020107547 | Erlinger et al. | Aug 2002 | A1 |
20020107548 | Bardy et al. | Aug 2002 | A1 |
20020107549 | Bardy et al. | Aug 2002 | A1 |
20020107553 | Hill et al. | Aug 2002 | A1 |
20020107559 | Sanders et al. | Aug 2002 | A1 |
20020120299 | Ostroff et al. | Aug 2002 | A1 |
20020120304 | Mest | Aug 2002 | A1 |
20020136328 | Shimizu | Sep 2002 | A1 |
20020138563 | Trivedi | Sep 2002 | A1 |
20020143264 | Ding et al. | Oct 2002 | A1 |
20020143369 | Hill et al. | Oct 2002 | A1 |
20020161410 | Kramer et al. | Oct 2002 | A1 |
20020165586 | Hill et al. | Nov 2002 | A1 |
20020169384 | Kowallik et al. | Nov 2002 | A1 |
20020169485 | Pless et al. | Nov 2002 | A1 |
20020183237 | Puskas | Dec 2002 | A1 |
20020193685 | Mate et al. | Dec 2002 | A1 |
20020198570 | Puskas | Dec 2002 | A1 |
20030003052 | Hampton | Jan 2003 | A1 |
20030004546 | Casey | Jan 2003 | A1 |
20030004549 | Hill et al. | Jan 2003 | A1 |
20030004552 | Plombon et al. | Jan 2003 | A1 |
20030023175 | Arzbaecher et al. | Jan 2003 | A1 |
20030023279 | Spinelli et al. | Jan 2003 | A1 |
20030036773 | Whitehurst et al. | Feb 2003 | A1 |
20030036778 | Ostroff et al. | Feb 2003 | A1 |
20030045904 | Bardy et al. | Mar 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030045914 | Cohen et al. | Mar 2003 | A1 |
20030050538 | Naghavi et al. | Mar 2003 | A1 |
20030055348 | Chazal et al. | Mar 2003 | A1 |
20030060857 | Perrson et al. | Mar 2003 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030069609 | Thompson | Apr 2003 | A1 |
20030073919 | Hampton et al. | Apr 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030078623 | Weinberg et al. | Apr 2003 | A1 |
20030078629 | Chen | Apr 2003 | A1 |
20030083241 | Young | May 2003 | A1 |
20030083587 | Ferek-Petric | May 2003 | A1 |
20030088027 | Chin et al. | May 2003 | A1 |
20030088278 | Bardy et al. | May 2003 | A1 |
20030088279 | Rissmann et al. | May 2003 | A1 |
20030088280 | Ostroff | May 2003 | A1 |
20030088281 | Ostroff et al. | May 2003 | A1 |
20030088282 | Ostroff | May 2003 | A1 |
20030088283 | Ostroff | May 2003 | A1 |
20030088286 | Ostroff et al. | May 2003 | A1 |
20030097153 | Bardy et al. | May 2003 | A1 |
20030100924 | Foreman et al. | May 2003 | A1 |
20030105493 | Salo et al. | Jun 2003 | A1 |
20030105497 | Zhu et al. | Jun 2003 | A1 |
20030121519 | Estes et al. | Jul 2003 | A1 |
20030139780 | Markowitz et al. | Jul 2003 | A1 |
20030149450 | Mayberg | Aug 2003 | A1 |
20030149457 | Tcheng et al. | Aug 2003 | A1 |
20030171687 | Irie et al. | Sep 2003 | A1 |
20030178031 | Du Pen et al. | Sep 2003 | A1 |
20030181951 | Cates | Sep 2003 | A1 |
20030195578 | Perron et al. | Oct 2003 | A1 |
20030204146 | Carlson | Oct 2003 | A1 |
20030209246 | Schroeder et al. | Nov 2003 | A1 |
20030212436 | Brown | Nov 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030216789 | Deem et al. | Nov 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20030236558 | Whitehurst | Dec 2003 | A1 |
20040010303 | Bolea | Jan 2004 | A1 |
20040019364 | Kieval et al. | Jan 2004 | A1 |
20040039605 | Bardy | Feb 2004 | A1 |
20040059240 | Cho et al. | Mar 2004 | A1 |
20040073093 | Hatlestad | Apr 2004 | A1 |
20040111021 | Olson | Jun 2004 | A1 |
20040111040 | Ni et al. | Jun 2004 | A1 |
20040111041 | Ni et al. | Jun 2004 | A1 |
20040116981 | Mazar | Jun 2004 | A1 |
20040122487 | Hatlestad et al. | Jun 2004 | A1 |
20040122488 | Mazar et al. | Jun 2004 | A1 |
20040128161 | Mazar et al. | Jul 2004 | A1 |
20040133079 | Mazar et al. | Jul 2004 | A1 |
20040134496 | Cho et al. | Jul 2004 | A1 |
20040163648 | Burton | Aug 2004 | A1 |
20040172074 | Yoshihito | Sep 2004 | A1 |
20040176695 | Poezevara | Sep 2004 | A1 |
20040176809 | Cho et al. | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040199210 | Shelchuk | Oct 2004 | A1 |
20040210154 | Kline | Oct 2004 | A1 |
20040210261 | King et al. | Oct 2004 | A1 |
20040215240 | Lovett et al. | Oct 2004 | A1 |
20040215289 | Fukui | Oct 2004 | A1 |
20040230229 | Lovett et al. | Nov 2004 | A1 |
20040230230 | Lindstrom | Nov 2004 | A1 |
20040230243 | Haefner | Nov 2004 | A1 |
20040243012 | Ciaccio et al. | Dec 2004 | A1 |
20040254616 | Rossing et al. | Dec 2004 | A1 |
20050004615 | Sanders | Jan 2005 | A1 |
20050039745 | Stahmann et al. | Feb 2005 | A1 |
20050042589 | Hatlestad et al. | Feb 2005 | A1 |
20050043644 | Stahmann et al. | Feb 2005 | A1 |
20050043652 | Lovett et al. | Feb 2005 | A1 |
20050043772 | Stahmann et al. | Feb 2005 | A1 |
20050061315 | Lee et al. | Mar 2005 | A1 |
20050061319 | Hartley et al. | Mar 2005 | A1 |
20050065447 | Lee et al. | Mar 2005 | A1 |
20050065572 | Hartley et al. | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050069322 | Tegge, Jr. et al. | Mar 2005 | A1 |
20050085864 | Schulman et al. | Apr 2005 | A1 |
20050085865 | Tehrani | Apr 2005 | A1 |
20050096705 | Pastore et al. | May 2005 | A1 |
20050101841 | Kaylor et al. | May 2005 | A9 |
20050107838 | Lovett et al. | May 2005 | A1 |
20050113710 | Stahmann et al. | May 2005 | A1 |
20050119711 | Cho et al. | Jun 2005 | A1 |
20050131467 | Boveja | Jun 2005 | A1 |
20050137645 | Voipio et al. | Jun 2005 | A1 |
20050142070 | Hartley et al. | Jun 2005 | A1 |
20050143779 | Libbus | Jun 2005 | A1 |
20050143785 | Libbus | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050145246 | Hartley et al. | Jul 2005 | A1 |
20050149126 | Libbus | Jul 2005 | A1 |
20050149127 | Libbus | Jul 2005 | A1 |
20050149128 | Heil, Jr. et al. | Jul 2005 | A1 |
20050149129 | Libbus et al. | Jul 2005 | A1 |
20050149131 | Libbus et al. | Jul 2005 | A1 |
20050149132 | Libbus | Jul 2005 | A1 |
20050149133 | Libbus et al. | Jul 2005 | A1 |
20050149143 | Libbus | Jul 2005 | A1 |
20050149155 | Scheiner et al. | Jul 2005 | A1 |
20050149156 | Libbus et al. | Jul 2005 | A1 |
20050159784 | Arceta | Jul 2005 | A1 |
20050165323 | Montgomery et al. | Jul 2005 | A1 |
20050197675 | David et al. | Sep 2005 | A1 |
20050240240 | Park et al. | Oct 2005 | A1 |
20060047333 | Tockmann et al. | Mar 2006 | A1 |
20060079945 | Libbus | Apr 2006 | A1 |
20060106428 | Libbus et al. | May 2006 | A1 |
20060106429 | Libbus et al. | May 2006 | A1 |
20060116737 | Libbus | Jun 2006 | A1 |
20060122675 | Libbus et al. | Jun 2006 | A1 |
20060206153 | Libbus et al. | Sep 2006 | A1 |
20060206154 | Libbus et al. | Sep 2006 | A1 |
20060217772 | Libbus et al. | Sep 2006 | A1 |
20060224188 | Libbus et al. | Oct 2006 | A1 |
20060293714 | Salo et al. | Dec 2006 | A1 |
20070005114 | Salo et al. | Jan 2007 | A1 |
20070093875 | Chavan et al. | Apr 2007 | A1 |
20070112388 | Salo | May 2007 | A1 |
20070142741 | Berthon-Jones et al. | Jun 2007 | A1 |
20070142871 | Libbus et al. | Jun 2007 | A1 |
20070150014 | Kramer et al. | Jun 2007 | A1 |
20070161873 | Ni et al. | Jul 2007 | A1 |
20070239057 | Pu et al. | Oct 2007 | A1 |
20070282215 | Ni et al. | Dec 2007 | A1 |
Number | Date | Country |
---|---|---|
0547734 | Jun 1993 | EP |
0750920 | Jan 1997 | EP |
0770407 | May 1997 | EP |
1038498 | Sep 2000 | EP |
1162125 | Dec 2001 | EP |
1 172 125 | Jan 2002 | EP |
1234597 | Aug 2002 | EP |
1304137 | Apr 2003 | EP |
1317943 | Jun 2003 | EP |
1486232 | Dec 2004 | EP |
1541193 | Jun 2005 | EP |
WO8402080 | Jun 1984 | WO |
WO8605965 | Oct 1986 | WO |
WO9203983 | Mar 1992 | WO |
WO9217240 | Oct 1992 | WO |
WO9220402 | Nov 1992 | WO |
WO9301862 | Feb 1993 | WO |
WO9904841 | Feb 1999 | WO |
WO0009206 | Feb 2000 | WO |
WO0017615 | Mar 2000 | WO |
WO0124876 | Apr 2001 | WO |
WO0143804 | Jun 2001 | WO |
WO0176689 | Oct 2001 | WO |
WO0226318 | Apr 2002 | WO |
WO0234327 | May 2002 | WO |
WO02085448 | Oct 2002 | WO |
WO03003905 | Jan 2003 | WO |
WO03011388 | Feb 2003 | WO |
WO03041559 | May 2003 | WO |
WO03075744 | Sep 2003 | WO |
WO03076008 | Sep 2003 | WO |
WO03082080 | Oct 2003 | WO |
WO03099373 | Dec 2003 | WO |
WO03099377 | Dec 2003 | WO |
WO2004012814 | Feb 2004 | WO |
WO2004062485 | Jul 2004 | WO |
WO2004084990 | Oct 2004 | WO |
WO2004084993 | Oct 2004 | WO |
WO2004103455 | Dec 2004 | WO |
WO2004105870 | Dec 2004 | WO |
WO2004110549 | Dec 2004 | WO |
WO2005018739 | Mar 2005 | WO |
WO2005028029 | Mar 2005 | WO |
WO2005042091 | May 2005 | WO |
WO2005053788 | Jun 2005 | WO |
WO2005063332 | Jul 2005 | WO |
WO2005065771 | Jul 2005 | WO |
WO2006031331 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20050042589 A1 | Feb 2005 | US |